Evelo Biosciences, Inc.
EVLO
$0.00
$0.00-20.00%
OTC PK
| 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | 09/30/2022 | |
|---|---|---|---|---|---|
| Net Income | 59.55% | 30.95% | 15.14% | 17.84% | 9.39% |
| Total Depreciation and Amortization | -65.30% | -20.45% | -13.93% | -2.79% | -17.18% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -7.79% | 6.86% | -37.41% | 13.97% | 15.58% |
| Change in Net Operating Assets | -298.18% | -280.06% | 131.32% | -24.34% | 72.84% |
| Cash from Operations | 53.92% | 25.25% | 29.92% | 16.72% | 16.86% |
| Capital Expenditure | -422.22% | 100.00% | 92.16% | -151.47% | 98.89% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | 5,800.00% | 100.00% | 92.16% | -148.00% | 98.89% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 3,555.04% | -100.00% | -72.09% | -- | 100.91% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -100.00% | -1,858.33% | -- | -- |
| Cash from Financing | 2,790.23% | -100.00% | -270.09% | 1,480.16% | 100.91% |
| Foreign Exchange rate Adjustments | 95.21% | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 140.41% | -137.89% | 29.34% | 23.22% | 16.97% |